Weekly Spotlight - 14.11.24

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

In the News

Emerging Therapies for Generalised Myasthenia Gravis: Promising Advances

The article discusses emerging treatments for Generalised Myasthenia Gravis (gMG), highlighting novel therapies targeting specific disease pathways. Complement inhibitors and FcRn antagonists show promise in improving treatment efficacy and safety. Experts express optimism about these advancements, which aim to address current treatment gaps and enhance patient care.

Inebilizumab Shows Promise in Reducing Steroid Use for Myasthenia Gravis

Inebilizumab, an anti-CD19 monoclonal antibody, shows promise for treating generalised myasthenia gravis. The MINT trial highlights its ability to reduce steroid use while maintaining safety and efficacy. This innovative treatment targets B cells, offering hope for patients unresponsive to existing therapies. Further analysis and publication are forthcoming.

Inebilizumab Shows Promise in Myasthenia Gravis Treatment

The MINT trial showed inebilizumab significantly improved symptoms in myasthenia gravis patients, offering hope for those struggling with the disease. The study highlighted its safety and efficacy, particularly in acetylcholine receptor and MuSK autoantibody-positive patients, marking a promising advancement in treatment options.

Nipocalimab: A Breakthrough for Adolescent Myasthenia Gravis Treatment

Nipocalimab shows promise for adolescents with myasthenia gravis, reducing IgG levels and improving function with minimal side effects. Dr Jonathan Strober highlights its significance, noting the drug's potential to change paediatric treatment. The study supports safe dosing for younger patients, addressing insurance challenges and expanding treatment options.